CANONSBURG, Pa. (AP) -- Generic drugmaker Mylan Inc. said Friday it received Food and Drug Administration approval for another version of Lithobid, a treatment for manic episodes of manic depressive illness.
The Canonsburg, Pa., company said it received approval for 450-milligram lithium carbonate extended-release tablets, and it will start selling them immediately. The treatment had U.S. sales of about $15.2 million in the year that ended June 30.
Last month, Mylan started selling 300-milligram tablets of lithium carbonate.
Mylan's stock was unchanged in premarket trading.
